MICA AI Medical, Sheba’s ARC ecosystem Israeli medtech startup, has developed new technologies for the early detection of breast cancer that recently raised 3M$ in funding FinSMEs.

MICA’s technologies play a crucial role in global healthcare due to the alarming prevalence of breast cancer, which remains the most common cancer among women worldwide. In the past year alone, there were over 2.2 million reported cases, underscoring the urgent need for effective solutions provided by MICA’s technologies. MICA promises to save lives and improve life quality by providing a unique holistic solution for dense breasts (40% of women). In addition, MICA aims to save 30% of the valuable time per checkup, save money and other financial resources, and reduce the risk of lawsuits by a third.

MICA AI Medical developed three products, one of which is the DENISE technology. DENISE (Dense Breast Innovative System) is an AI-based algorithm that provides decision support to the radiologist, which was developed, tested, and validated at Sheba’s ARC Innovation Center and is already integrated into Sheba Medical Center’s clinical workflows. Sheba’s ARC Center (Accelerate, Redesign, Collaborate) for digital innovation brings together all aspects of digital medicine for the common goal of redesigning healthcare. In addition to incubating outside startups, ARC releases internally developed technology.

Due to the alarming prevalence of breast cancer, MICA's technologies play a crucial role in global healthcare.

DENISE AI Helps in Detecting Breast Cancer

Mica AI’s DENISE technology aids radiologists in detecting breast cancer and malignancies by facilitating accurate and practical interpretations of contrast-enhanced mammograms (CEM). While mammogram images make it challenging to determine whether the mass in the image is malignant or benign, MICA uses a set of questions and machine learning to aid the examining physician in deciding the nature of the mass without an invasive biopsy.
The revolutionary platform showed an increase in mammography accuracy to 90%, which reduced overdiagnosis and unnecessary, painful, and invasive biopsies by 30%.

The system supports the physician’s decision to perform a biopsy by producing immediate and accurate proximity of the mass being a cancerous tumor. It is essential to avoid unnecessary biopsies, as many women experience extreme anxiety and stress upon undergoing the procedure. In addition, it takes a few weeks to receive the result of a biopsy, which could be very nerve-wracking since, during this time, the woman is convinced she has cancer. The MICA platform prevents this stressful situation because the patient receives a result within minutes.

Sheba has engaged in numerous collaborations to advance healthcare and medicinal science. By actively partnering with leading academic institutions, pharmaceutical companies, and research organizations, Sheba drives progress and promotes transformative healthcare solutions. MICA AI, born at Sheba’s innovation center, achieved significant research advancement and won the Best NeCommer in the 2021 Middle East Startup Awards. Sheba Medical Center recognizes MICA’s immense potential, believes in the importance of promoting international collaborations, and eagerly anticipates making significant strides in breast cancer medicine and beyond.

More Posts

The Jewish Federation of Greater Washington’s Solidarity Visit to Israel

The Jewish Federation of Greater Washington’s Solidarity Visit to Israel

In a profound display of solidarity, Gil Preuss, CEO of the Jewish Federation of Greater Washington, recently visited Israel to bring support and witness the immediate needs of the Israeli people. Preuss’s mission included delivering personal messages of encouragement to Israeli soldiers and engaging with frontline medical facilities providing critical care to those affected by the war.

read more